Strategic Realignment and Market Context

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management attributes current stock performance to a broader 'evacuation' of the sub-$200 million market cap sector, where institutional capital has rotated heavily toward mega-cap AI companies.

• The firm is shifting from a high-volume launch model (3-5 companies annually) to a 'rifle-shot' approach, focusing on monetizing four core assets to avoid shareholder dilution in a depressed market.

• Operational strategy is being restructured to achieve a lean platform with approximately $5 million to $6 million in annual expenses, offset by transaction fees to ensure sustainability.

• Management views the current microcap environment as being 'on the floor,' suggesting that a potential downturn in mega-cap stocks could trigger a rotation back into undervalued small-cap assets.

• The company is actively seeking to partner or sell its Public Ventures clearing platform to focus resources on its highest-leverage activity: launching and scaling 'big idea' enterprises.

• Strategic focus for PatentVest has pivoted to an AI-enabled 'law firm of the future' model, utilizing an Arizona ABS structure to allow corporate ownership of legal practices.

Value Inflection Points and Strategic Outlook

• Paulex Bio is expected to file for an IPO in Q4 2026, with critical clinical data regarding beta cell production anticipated in early 2027.

• The firm expects to finalize a partnership or sale of the Public Ventures clearing platform within the next quarter to reduce overhead and realize strategic value.

• eXoZymes is projected to secure commercial partnerships and contract manufacturing relationships soon, which management believes will validate its ability to scale synthetic biology.

• MDB plans to spin out PatentVest as an independent entity funded by outside investors to remove development costs from the MDB balance sheet while retaining equity upside.

• Future revenue is expected to remain 'lumpy' as the firm prioritizes high-conviction transactions over volume until the microcap market backdrop improves.

Portfolio Risks and Structural Changes

• Management acknowledged that the stock is trading below its IPO price, attributing this to the failure of recent launches to reach the $1 billion valuations seen in prior cycles.

• The firm is transitioning its business model to protect against dilution, explicitly stating they are not looking to raise more capital at the MDB level.

• HeartBeam's strategy has been redirected toward capital-efficient technology licensing and partnerships rather than self-launching products to preserve cash and minimize dilution.

• The success of the portfolio remains highly dependent on the 'rotation of the asset class' and the ability of small companies to gain institutional visibility.